Cacnex has been committed to providing comprehensive services for Chinese and North American companies or investors in cross-border cooperation and asset acquisitions in innovative technologies (mainly in the field of healthcare), thereby promoting the commercialization and internationalization of new technologies.

 

With partnerships spanning hundreds of biotech and pharmaceutical firms across the U.S., Canada, and China, Cacnex leverages deep insights into corporate strategies, key technologies, and product pipelines to identify commercially valuable collaboration opportunities. 

 

Beyond facilitating transactions, Cacnex focuses on enhancing asset value through licensing and strategic partnerships.

 

By collaborating closely with local governments and healthcare regulators, Cacnex enables foreign pharma and biotech firms to accelerate the introduction of new drugs and devices into the Chinese market through a streamlined regulatory pathway.​